STOCK TITAN

INSBANK Parent InsCorp Reports Second Quarter Results, Declares Quarterly Cash Dividend, and Authorizes Share Repurchase

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
buybacks dividends earnings

InsCorp, Inc. reported net income of $1,820,000, or $0.63 per share, in Q2 2024, up from $1,763,000 in Q1 2024. The company achieved a ROAE of 10.1% and operating EPS of $0.65. Loan originations increased to $57 million in Q2, up from $23 million in Q1, with strength in Medquity, CRE, C&D, and C&I loans. The loan pipeline grew to $79 million. Medquity reported 9% Y/Y loan growth. Revenue declined 1.1% Y/Y but improved 2.7% LQA to $6,212,000. The net interest margin was 3.08%. Asset quality remains healthy with no net chargeoffs. InsCorp's Board authorized a share repurchase of 125,000 shares and declared a quarterly dividend of $0.10 per share.

InsCorp, Inc. ha riportato un utile netto di 1.820.000 dollari, ovvero 0,63 dollari per azione, nel secondo trimestre del 2024, rispetto a 1.763.000 dollari nel primo trimestre del 2024. L'azienda ha registrato un ROAE del 10,1% e un EPS operativo di 0,65 dollari. Le origini dei prestiti sono aumentate a 57 milioni di dollari nel secondo trimestre, rispetto a 23 milioni di dollari nel primo trimestre, con punti di forza nei prestiti Medquity, CRE, C&D e C&I. Il portafoglio prestiti è cresciuto a 79 milioni di dollari. Medquity ha riportato una crescita dei prestiti del 9% rispetto all'anno precedente. I ricavi sono diminuiti dell'1,1% anno su anno ma sono migliorati del 2,7% rispetto all'ultimo trimestre a 6.212.000 dollari. Il margine d'interesse netto era del 3,08%. La qualità delle attività rimane sana senza addebiti netti. Il Consiglio di InsCorp ha autorizzato un riacquisto di azioni di 125.000 azioni e ha dichiarato un dividendo trimestrale di 0,10 dollari per azione.

InsCorp, Inc. reportó un ingreso neto de 1.820.000 dólares, o 0,63 dólares por acción, en el segundo trimestre de 2024, un aumento respecto a 1.763.000 dólares en el primer trimestre de 2024. La compañía logró un ROAE del 10,1% y un EPS operativo de 0,65 dólares. Las originaciones de préstamos aumentaron a 57 millones de dólares en el segundo trimestre, subiendo desde 23 millones de dólares en el primer trimestre, con fortaleza en préstamos Medquity, CRE, C&D y C&I. El pipeline de préstamos creció a 79 millones de dólares. Medquity reportó un crecimiento de préstamos del 9% interanual. Los ingresos disminuyeron un 1,1% interanual, pero mejoraron un 2,7% en comparación con el último trimestre, alcanzando 6.212.000 dólares. El margen de interés neto fue del 3,08%. La calidad de los activos se mantiene saludable sin cargos netos. La Junta de InsCorp autorizó un recompra de acciones de 125.000 acciones y declaró un dividendo trimestral de 0,10 dólares por acción.

InsCorp, Inc.는 2024년 2분기에 1,820,000달러의 순이익, 즉 주당 0.63달러를 기록했으며, 이는 2024년 1분기의 1,763,000달러에서 증가한 수치입니다. 회사는 10.1%의 ROAE와 0.65달러의 운영 EPS를 달성했습니다. 대출 발행량은 2분기에 5,700만 달러로 증가했으며, 이는 1분기의 2,300만 달러에서 상승한 것입니다. Medquity, CRE, C&D, C&I 대출에서 강세를 보였습니다. 대출 파이프라인은 7,900만 달러로 성장했습니다. Medquity는 전년 대비 9%의 대출 성장을 보고했습니다. 연간 수익은 1.1% 감소했지만, 전 분기 대비 2.7% 증가하여 6,212,000달러에 달했습니다. 순이자 마진은 3.08%였습니다. 자산의 질은 건강하며, 순손실은 없습니다. InsCorp의 이사회는 125,000주의 자사주 매입을 승인하고, 주당 0.10달러의 분기 배당금을 선언했습니다.

InsCorp, Inc. a rapporté un revenu net de 1.820.000 dollars, soit 0,63 dollars par action, au 2ème trimestre 2024, en hausse par rapport à 1.763.000 dollars au 1er trimestre 2024. La société a atteint un ROAE de 10,1% et un EPS opérationnel de 0,65 dollars. Les origines de prêts ont augmenté à 57 millions de dollars au 2ème trimestre, contre 23 millions de dollars au 1er trimestre, avec des performances solides dans les prêts Medquity, CRE, C&D et C&I. Le pipeline de prêts a crû à 79 millions de dollars. Medquity a rapporté une croissance des prêts de 9 % d'une année sur l'autre. Les revenus ont diminué de 1,1 % d'une année sur l'autre mais ont augmenté de 2,7 % par rapport au dernier trimestre, atteignant 6.212.000 dollars. La marge d'intérêt nette était de 3,08%. La qualité des actifs reste saine sans annulations nettes. Le conseil d'administration d'InsCorp a autorisé un rachat de 125.000 actions et a déclaré un dividende trimestriel de 0,10 dollars par action.

InsCorp, Inc. berichtete über einen Nettoertrag von 1.820.000 US-Dollar, also 0,63 US-Dollar pro Aktie, im 2. Quartal 2024, ein Anstieg von 1.763.000 US-Dollar im 1. Quartal 2024. Das Unternehmen erzielte eine ROAE von 10,1% und ein operatives EPS von 0,65 US-Dollar. Die Kreditvergaben stiegen im 2. Quartal auf 57 Millionen US-Dollar, gegenüber 23 Millionen US-Dollar im 1. Quartal, mit starken Ergebnissen in den Bereichen Medquity, CRE, C&D und C&I Kredite. Die Kreditpipeline wuchs auf 79 Millionen US-Dollar. Medquity meldete ein Kreditwachstum von 9% im Jahresvergleich. Der Umsatz sank im Jahresvergleich um 1,1%, verbesserte sich jedoch im Vergleich zum letzten Quartal um 2,7% auf 6.212.000 US-Dollar. Die Nettomarge betrug 3,08%. Die Asset-Qualität bleibt gesund ohne Nettobelastungen. Der Vorstand von InsCorp genehmigte einen Aktienrückkauf von 125.000 Aktien und erklärte eine Quartalsdividende von 0,10 US-Dollar pro Aktie.

Positive
  • Net income increased to $1,820,000 in Q2 2024, up from $1,763,000 in Q1 2024
  • Loan originations grew to $57 million in Q2 2024, up from $23 million in Q1 2024
  • Loan pipeline increased to $79 million, up from $67 million a quarter ago
  • Medquity segment reported 9% Y/Y loan growth
  • Noninterest income grew 37% Y/Y to $590,000 in Q2 2024
  • Net interest margin improved to 3.08% in Q2 2024 from 2.94% in Q1 2024
  • Board authorized share repurchase of 125,000 shares (4.3% of outstanding shares)
  • Declared quarterly dividend of $0.10 per share, a 17.6% annualized increase from 2023
Negative
  • Revenue declined 1.1% Y/Y to $6,212,000 in Q2 2024
  • Net interest income declined 4% Y/Y to $5,622,000
  • Expense growth of 5% Y/Y to $3,676,000
  • Cost of deposits increased 88 basis points Y/Y to 3.89% in Q2 2024
  • Nonperforming assets increased to 1.08% of loans from 0.18% a year ago

NASHVILLE, Tenn., Aug. 2, 2024 /PRNewswire/ -- InsCorp, Inc. reported net income of $1,820,000, or $0.63 per share, in the second quarter of 2024 ("2Q24") versus $1,763,000, or $0.61 per share, in 1Q24 and respective levels of $1,776,000 and $0.62 in 2Q23. "While we're pleased with growth in net income over the prior quarter, the more exciting aspect of Q2 was key additions to our team," said Jim Rieniets, President & CEO of INSBANK. "During the quarter a number of experienced, local professionals joined us in both production and operations roles, which should allow us to maintain growth momentum across our business lines." InsCorp generated a ROAE of 10.1% in 2Q24 versus 10.0% in 1Q24 and 10.8% in 2Q23.

Excluding gains and losses from hedging activities, operating EPS of $0.65 in 2Q24 compared to $0.67 in 1Q24 and $0.70 in 2Q23. A lower tax rate in 2Q24 benefitted EPS in the quarter by $0.01 compared to 1Q24 and 2Q23. Excluding gains and losses from hedging activities, pretax income of $2,461,000 in 2Q24 was 4.8% lower than the previous quarter and 7.0% lower than 2Q23. The mark-to-market pretax adjustment to interest rate floor contracts was ($93,000) in 2Q24 versus ($252,000) in 1Q24 and ($304,000) in 2Q23, which reflected changes in the futures market for interest rates during the quarter. These hedging contracts remain in place as an insurance policy against an unexpected drop in rates.

Bank-wide loan originations continued to gain momentum—increasing to $57 million in 2Q24 versus $23 million in 1Q24, $48 million in 4Q23, and $26 million in 3Q23. Originations reflected strength in Medquity, commercial real estate ("CRE"), construction ("C&D"), and commercial and industrial ("C&I") loans. The loan pipeline increased to $79 million, as of June 30, 2024, which exceeded $67 million a quarter ago, $53 million at 2023-end, $19 million at 3Q24-end, and $35 million a year ago. Choppy loan growth over the past year (+1% year-over-year; "Y/Y") resulted from elevated payoffs over much of the year and a smaller pipeline in 3Q23 and 4Q23.

Given a resumption of loan growth to 4% on a linked quarter annualized basis ("LQA") and continued momentum in origination and the pipeline levels in 2Q24, management is optimistic that loan growth will improve during the remainder of 2024. Coupled with the arrival of funded loan growth of $7.1 million late in 2Q24, unfunded commitment growth in construction loans of $17.6M in 2Q24, should benefit net interest income and margin comparisons on a LQ basis in 3Q24 and 4Q24. Growth in the loan pipeline to $79 million represents a positive signal for growth in the second half of 2024, too.

Medquity, INSBANK's healthcare business, continues to provide solid growth and diversification given its national focus and reduced sensitivity to economic and real estate cycles. In 2Q24, Medquity reported loan growth of 9% Y/Y (+6% LQA) to $209 million, lifting the segment's loans to nearly 31% of the loan portfolio versus approximately 28% a year ago. Medquity's origination and pipeline activity remained strong and suggest solid growth over the balance of 2024.

"Our team had one of its best-ever quarters for new commercial deposit accounts, and the growth in noninterest bearing deposits reflects that activity," Rieniets stated. "As we have methodically focused on treasury resources in recent years, we're pleased to report both balance expansion in operating accounts as well as double-digit fee income growth on an annualized basis." Customer rationalization of low-cost deposits into a combination of higher yielding CDs, loan payoffs, and business investment has adversely affected INSBANK's deposit mix over the past two years. Importantly, demand deposit balances (noninterest bearing and interest bearing) increased 6% LQ to approximately $226 million at 2Q24-end, or 33.3% of deposits, compared to $213 million, or 31.7% of deposits, at 1Q24-end.

Revenue declined 1.1% Y/Y and improved 2.7% LQA to $6,212,000 in 2Q24. Net interest income declined 4% Y/Y (+2% LQA) to $5,622,000 in the quarter. This was mostly offset by noninterest income growth of 37% Y/Y (+9% LQA) to $590,000 in 2Q24. Expense growth of 5% Y/Y (+13% LQA) to $3,676,000 primarily consisted of increased personnel costs, as increases in occupancy and other lines were mostly offset by decreases in data processing and marketing and advertising.

The bank-level net interest margin of 3.08% in 2Q24 compared to 2.94% in 1Q24 and 3.38% in 2Q23. Although the Company benefited from an increase in the loan yield of 49 basis points ("bps") Y/Y to 6.73% in 2Q24, the cost of deposits increased 88 bps Y/Y (+8 bps LQ) to 3.89% in 2Q24. In a static interest rate environment, management would expect the margin to improve gradually given continued sales traction in transaction and money market accounts and funded loan growth. Management is optimistic that continued customer growth and a solid deposit customer pipeline will result in low-cost deposit balance growth going forward.

Asset quality measures remain healthy. Net chargeoffs represented 0.00% of average loans in 2Q24, unchanged compared to 1Q24 and 2Q23. Provision for credit losses totaled $75,000 in 2Q24 compared to $25,000 in 1Q24 and $141,000 in 2Q23. The allowance for credit losses represented 1.35% of loans, which remained above peer. The $140,000 increase in the allowance for unfunded commitments to $449,000, or 0.41% of unfunded loans, was mostly due to an increase in unfunded construction loan commitments of $17.6 million to $50.2 million, and to an increase in C&I commitments of $3.8 million to $36.5 million at 2Q24-end compared to 1Q24-end.

Nonperforming assets were 1.08% of loans versus 1.11% a quarter ago and 0.18% a year ago. The entire Y/Y change reflected the migration of one real estate secured credit from the bank's watch list at the end of 2023. Virtually all nonperforming assets are real estate-secured, for which specific reserves are relatively low. "Thus far in this cycle, the only observable sector in our portfolio experiencing stress is assisted living and memory care, where the pandemic reduced occupancy while increasing healthcare labor costs. Fortunately, both trends seem to be improving for operators in the sector, and this segment only accounts for 3.0% of our loan portfolio," Rieniets stated.

Although the aggregate level of watch list loans increased slightly compared to the prior quarter-end, the balance decreased approximately 41% Y/Y. The watch list to total loan ratio remained consistent with the level that existed prior to the pandemic. Loans 30-days past due represented 0.14% of loans, as of June 30, 2024, compared to 0.01% a quarter ago and 0.00% a year ago. The change in 30-day past dues represented the movement of one well-collateralized relationship.

C&D and CRE concentration levels remain below regulatory guidance and historically normal levels. Specifically, C&D increased + 0.9% linked quarter ("LQ") to 78.3% of total capital, while CRE increased 0.2% LQ to 284.9% of capital. C&D and CRE to capital ratios remained below the year ago levels of 87.2% and 312.6%, respectively, historically normal levels for the bank, and respective regulatory guidance levels of 100% and 300%. "Our bank is known to have a robust CRE risk management program, and those portfolio analytics continue to demonstrate durability," said CEO Rieniets. "Additionally, our consistent application of underwriting standards across the economic cycle positions INSBANK to take advantage of growth opportunities in the vibrant middle-Tennessee market." The decline in these ratios was due in part to payoffs and paydowns as well as growth in capital of 44% over the past three years, which exceeded the growth in non-farm, non-residential real estate of 29% over the same period. 

Measures of liquidity risk remain healthy and remain adequate to fund loan growth over the near-term. Specifically, balance sheet liquidity ended 2Q24 at $109 million compared to $110 million a quarter ago and $97 million a year ago. Estimated uninsured deposits were approximately 22% of total deposits at quarter-end versus 21% a quarter ago and 19% a year ago. Balance sheet liquidity and reciprocal deposit capacity of $139 million at 2Q24-end provide ample risk mitigation strategies and capacity to fund loan growth over the near-term, in addition to a solid deposit relationship pipeline.

Tangible book value increased 11.4%, or $2.54 per share, Y/Y to $24.89, as of June 30, 2024. InsCorp, Inc.'s tangible common equity ratio increased to 8.61%, as of June 30, 2024, versus 8.52% a quarter ago and 8.11% a year ago. Accumulated Other Comprehensive Income was ($1,437,000), or approximately 1.4% of bank-level tier-1 capital of $96,867,000. INSBANK remains well capitalized with a tier-1 leverage ratio of 11.63%, a common equity tier-1 capital ratio of 12.52%, and a total risk-based capital ratio of 13.77%. INSBANK's risk-based capital ratios increased by 75 bps Y/Y.

"With healthy equity ratios, internally generated capital of roughly 10%, and access to funding at the holding company level, we're fortunate to be in a position to enhance shareholder value in a variety of ways," said Jim Rieniets, CEO and Board Chairman of INSBANK and InsCorp, Inc. "Alongside supporting further balance sheet growth and dividends to shareholders, the recent share repurchase authorization provides another potential means of increasing shareholder returns." InsCorp, Inc.'s Board authorized the repurchase of 125,000 shares, or 4.3% of the Company's outstanding shares, through January 27, 2026, and the payment of a quarterly dividend of $0.10 per common share payable on September 6, 2024, to shareholders of record on August 16, 2024. The annualized quarterly dividend rate of $0.40 per share represents an annualized increase of 17.6% compared to dividends of $0.34 per share in 2023.

About INSBANK 

Since 2000, INSBANK has offered its clients highly personalized service provided by experienced relationship managers, while positioning itself as an innovator, utilizing technologies to deliver those services efficiently and conveniently. In addition to its commercial focused operation, INSBANK operates through three divisions, Medquity, TMA Medical Banking and Finworth.  Medquity offers healthcare banking solutions to physicians, partnerships, and practices nationwide, while TMA Medical Banking provides banking services specifically to members of the Tennessee Medical Association. Finworth offers nationally available virtual private client services for interest bearing deposits. INSBANK is owned by InsCorp, Inc., a Tennessee bank holding company. Shares of InsCorp, Inc., are traded on the OTCQX under the ticker symbol IBTN. The bank is headquartered in Nashville at 2106 Crestmoor Road and has an office in Brentwood at 5614 Franklin Pike Circle. For more information, please visit www.insbank.com.

 

InsCorp, Inc.

Consolidated Balance Sheets

(000's)

(unaudited)








June 30,


December 31,


June 30,


2024


2023


2023

Assets






Cash and Cash Equivalents

$                 5,203


$                 7,688


$                 4,237

Interest Bearing Deposits

47,383


49,757


39,416

Securities

56,056


58,162


53,264







Loans

684,533


681,558


675,627

  Allowance for Credit Losses

(9,216)


(9,126)


(9,536)

Net Loans

675,317


672,432


666,091







Premises and Equipment, net

12,568


12,715


12,879

Bank Owned Life Insurance

14,257


14,065


13,888

Restricted Equity Securities

9,379


8,890


8,758

Goodwill and Related Intangibles, net

1,091


1,091


1,091

Other Assets

13,082


12,290


13,904







  Total Assets

$             834,336


$             837,090


$             813,528







Liabilities and Shareholders' Equity






Liabilities






  Deposits







$               76,417


$               70,417


$               75,624


600,949


615,779


580,025


677,366


686,196


655,649







  Federal Home Loan Bank Advances

45,000


45,000


58,000

  Subordinated Debentures

17,360


17,348


17,500

  Notes Payable

8,516


8,750


8,250

  Other Liabilities

13,283


9,939


7,182

Total Liabilities

761,525


767,233


746,581







Shareholders' Equity






     Common Stock

33,426


33,112


32,906

     Treasury Stock

(3,882)


(3,869)


(3,857)

     Accumulated Retained Earnings

44,704


41,714


37,633

     Accumulated Other Comprehensive Income

(1,437)


(1,100)


265

     Total Stockholders' Equity

72,811


69,857


66,947

Total Liabilities & Shareholders' Equity

$             834,336


$             837,090


$             813,528







Tangible Book Value

$                 24.89


$                 23.93


$                 22.35

 

InsCorp, Inc.

Consolidated Statements of Income

(000's)

(Unaudited)












Three Months Ended


Six Months Ended


June 30, 2024


March 31, 2024


June 30, 2023


June 30, 2024


June 30, 2023











Interest Income

$               12,696


$               12,563


$               11,548


$               25,259


$               21,934

Interest Expense

7,074


6,970


5,694


14,044


10,308

Net Interest Income

5,622


5,593


5,854


11,215


11,626

Provision for Credit Losses

75


25


140


100


265

Noninterest Income










Service Charges on Deposit Accounts

71


67


51


138


98

Bank Owned Life Insurance

97


95


85


192


167

Other

422


415


294


837


592

Noninterest Expense










Salaries and Benefits

2,395


2,301


2,232


4,696


4,483

Occupancy and equipment

422


393


374


815


747

Data Processing

101


94


116


195


215

Marketing and Advertising

71


119


160


190


276

Other

687


652


616


1,339


1,237

Net Income from Operations

2,461


2,586


2,646


5,047


5,260











Gain (Loss) in Interest Rate Hedges

(93)


(252)


(304)


(345)


(238)

Income Before Income Taxes

2,368


2,334


2,342


4,702


5,022

Income Tax Expense

(548)


(571)


(566)


(1,119)


(1,196)

Net Income

$                 1,820


$                 1,763


$                 1,776


$                 3,583


$                 3,826











Earnings per Share

$                    0.63


$                    0.61


$                    0.62


$                    1.24


$                    1.33

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/insbank-parent-inscorp-reports-second-quarter-results-declares-quarterly-cash-dividend-and-authorizes-share-repurchase-302213792.html

SOURCE INSBANK

FAQ

What was InsCorp's (IBTN) net income for Q2 2024?

InsCorp (IBTN) reported a net income of $1,820,000, or $0.63 per share, in the second quarter of 2024.

How much did InsCorp's (IBTN) loan originations increase in Q2 2024?

InsCorp's (IBTN) loan originations increased to $57 million in Q2 2024, up from $23 million in Q1 2024.

What was InsCorp's (IBTN) net interest margin in Q2 2024?

InsCorp's (IBTN) net interest margin was 3.08% in Q2 2024, compared to 2.94% in Q1 2024 and 3.38% in Q2 2023.

How many shares did InsCorp (IBTN) authorize for repurchase in August 2024?

InsCorp (IBTN) authorized the repurchase of 125,000 shares, or 4.3% of the Company's outstanding shares, through January 27, 2026.

What dividend did InsCorp (IBTN) declare for Q2 2024?

InsCorp (IBTN) declared a quarterly dividend of $0.10 per common share, payable on September 6, 2024, to shareholders of record on August 16, 2024.

INSCORP INC

OTC:IBTN

IBTN Rankings

IBTN Latest News

IBTN Stock Data

66.11M
0.59%
Banks - Regional
Financial Services
Link
United States of America
Nashville